Related references
Note: Only part of the references are listed.Bevacizumab in Aggressive Pituitary Adenomas - Experience with 3 Patients
Katharina Osterhage et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2021)
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey
Ulf Elbelt et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Targeting the HIF2-VEGF axis in renal cell carcinoma
Toni K. Choueiri et al.
NATURE MEDICINE (2020)
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Lydia S. Lamb et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Pituitary carcinoma: Two case reports and review of literature
Lai Xu et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2020)
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
Omalkhaire M. Alshaikh et al.
ENDOCRINE PATHOLOGY (2019)
VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas
Ana Silvia Corlan et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2019)
Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma
Lauren E. Rotman et al.
WORLD NEUROSURGERY (2019)
Molecular Network Basis of Invasive Pituitary Adenoma: A Review
Qi Yang et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation-Positive Child
Pinaki Dutta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The Treatment of Refractory Pituitary Adenomas
Congxin Dai et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review
Yong Wang et al.
WORLD NEUROSURGERY (2019)
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
Xiaoshuang Liu et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors
Jose Eduardo Nunez et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma
Vincenzo Di Nunno et al.
ANTI-CANCER DRUGS (2018)
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Lesley J. Scott
DRUGS (2018)
Vision Loss from Choroidal and Pituitary Metastases Secondary to Renal Cell Carcinoma: A Case Report
Laura D. Selby et al.
NEURO-OPHTHALMOLOGY (2018)
Dopamine Agonists for Pituitary Adenomas
Odelia Cooper et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Pituitary Metastasis of Thyroid Carcinoma: A Case Report
Juliana Souza Mota et al.
AMERICAN JOURNAL OF CASE REPORTS (2018)
VEGF as a potential target in lung cancer
Daniela Frezzetti et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model
Norbert Chauvet et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
Waseem Touma et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report
Jasmine Shell et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2017)
Type 2 gastric neuroendocrine tumor: report of one case
Yuanliang Li et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentration
Muhammad M. Hammami et al.
BMC CANCER (2015)
Lactotrophs: The new and major source for VEGF secretion and the influence of ECM on rat pituitary function in vitro
Joachim Alfer et al.
ONCOLOGY REPORTS (2015)
Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature
Maria Kurowska et al.
CASE REPORTS IN ENDOCRINOLOGY (2015)
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy
Youwei Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Epidemiology and etiopathogenesis of pituitary adenomas
Elena D. Aflorei et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
VEGFA and tumour angiogenesis
L. Claesson-Welsh et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence
Ruth Sanchez-Ortiga et al.
PITUITARY (2013)
Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment
Lin Yang et al.
CHINESE JOURNAL OF CANCER (2013)
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
T. C. Schneider et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Abstracts of the 9th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 79, 2012, Copenhagen, Denmark
NEUROENDOCRINOLOGY (2012)
Anti-VEGF therapy in pituitary carcinoma
Leon D. Ortiz et al.
PITUITARY (2012)
Inhibitory Effects of Antivascular Endothelial Growth Factor Strategies in Experimental Dopamine-Resistant Prolactinomas
Guillermina Maria Luque et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Pathogenesis of pituitary tumors
Shlomo Melmed
NATURE REVIEWS ENDOCRINOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inhibitory Effects of Anti-VEGF Antibody on the Growth and Angiogenesis of Estrogen-induced Pituitary Prolactinoma in Fischer 344 Rats: Animal Model of VEGF-targeted Therapy for Human Endocrine Tumors
Katsuhiro Miyajima et al.
ACTA HISTOCHEMICA ET CYTOCHEMICA (2010)
VEGF and CD31 Association in Pituitary Adenomas
Carolina Cristina et al.
ENDOCRINE PATHOLOGY (2010)
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1
Nina Korsisaari et al.
CLINICAL CANCER RESEARCH (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment
Masamichi Kurosaki et al.
NEUROLOGICAL RESEARCH (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
J. G. Christensen
ANNALS OF ONCOLOGY (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug Insight: VEGF as a therapeutic target for breast cancer
Bryan P. Schneider et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Angiogenesis in life, disease and medicine
P Carmeliet
NATURE (2005)
Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas
M Niveiro et al.
HUMAN PATHOLOGY (2005)
Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice
C Cristina et al.
ENDOCRINOLOGY (2005)
Correlation of VEGF production with IL1α and IL6 secretion by human pituitary adenoma cells
SA Borg et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The prevalence of pituitary adenomas - A systematic review
S Ezzat et al.
CANCER (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas
P Viacava et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Microvessel density in pituitary adenomas and carcinomas
S Vidal et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2001)
Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome
HE Turner et al.
JOURNAL OF ENDOCRINOLOGY (2000)
Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas
T Iuchi et al.
ACTA NEUROCHIRURGICA (2000)
Share Paper
